<ѻýҕl>CAR T-Cell Therapy Makes Strong Case for Earlier Use in Lymphomaѻýҕl> Large increases in event-free survival with two CAR T-cell products in second line Dec 11, 2021
<ѻýҕl>Chemo-Free Regimen Highly Active in Older Mantle Cell Lymphoma Patientsѻýҕl> Overall response rate of 96% with ibrutinib-rituximab, but cardiotoxicity a possible issue Nov 29, 2021
<ѻýҕl>Novel Triplet Yields Undetectable MRD Status in 90% of CLL/SLL Patientsѻýҕl> Zanubrutinib plus obinutuzumab and venetoclax was also well tolerated Nov 29, 2021
<ѻýҕl>Ceritinib Shows Promise in ALK-Positive Pediatric Malignanciesѻýҕl> Responses seen in neuroblastoma, among other tumors Nov 17, 2021
<ѻýҕl>Ibrutinib Boosts Survival in Younger Patients With Certain DLBCL Subtypesѻýҕl> New analysis "casts the PHOENIX trial in a new light," authors say Nov 04, 2021
<ѻýҕl>Ibrutinib-Rituximab Wins Out in Waldenstrom's Macroglobulinemiaѻýҕl> Risk of disease progression or death reduced by 75% versus rituximab alone Oct 11, 2021
<ѻýҕl>9/11 Responders Face Higher Risk of Multiple Cancersѻýҕl> Longer follow-up sheds light on the long-term consequences of exposure to disaster site Sep 10, 2021
<ѻýҕl>Lymphoma in RA: Disease Activity Mattersѻýҕl> Strongest risk factors were baseline disease activity scores and bone erosions Sep 08, 2021
<ѻýҕl>Non-Chemo Regimen Highly Active in R/R Hodgkin Lymphomaѻýҕl> Three-year progression-free survival of 77%, including 91% after stem-cell transplantation Aug 23, 2021
<ѻýҕl>How CAR T-Cell Therapy Measures Up in Follicular Lymphomaѻýҕl> Better response rates and survival with axicabtagene ciloleucel versus external control group Jun 15, 2021
<ѻýҕl>COVID Vaccine Protection; 'Until You Die From the Cancer'; What's Palliative Care?ѻýҕl> News, features, and commentary about cancer-related issues Jun 10, 2021
<ѻýҕl>Another CAR-T Impresses in Follicular Lymphomaѻýҕl> Complete responses in 66% of patients with relapsed or refractory disease Jun 08, 2021
<ѻýҕl>Thiotepa-Based Conditioning Promising for Primary CNS Lymphomaѻýҕl> Commonly used regimens with autologous transplant improved survival May 06, 2021
<ѻýҕl>Add-On PI3K Inhibitor Wins in Relapsed, Indolent NHLѻýҕl> Adding copanlisib to rituximab also doubled CR rate, with manageable toxicity Apr 10, 2021
<ѻýҕl>Op-Ed: Blood Cancer Patients Need More COVID Vax Answersѻýҕl> Patients are left wondering, "will I be protected?" Mar 24, 2021
<ѻýҕl>Anti-CD20 Drugs Tied to Severe COVID in Cancer Patientsѻýҕl> Plus: Active chemo treatment may not be a COVID risk factor Feb 05, 2021
<ѻýҕl>JAK Inhibitor Misses Endpoint in Safety Study. Now What?ѻýҕl> Major blow to popular class of oral rheumatology drugs Jan 27, 2021
<ѻýҕl>Non-Hodgkin Lymphoma: Bispecific Antibodies Impress in Refractory Diseaseѻýҕl> Odronextamab, epcoritamab surpass 90% response threshold in early trials Dec 11, 2020
<ѻýҕl>Blood Cancers and COVID-19: 'A Medically Vulnerable' Groupѻýҕl> Patients with hematologic malignancies and SARS-CoV-2 face higher risks for infection, death Dec 06, 2020
<ѻýҕl>HIV: Don't Quit on Hope, Says 'London Patient'ѻýҕl> IAC roundtable addresses prospects for cure, now proven to be possible Jul 06, 2020
<ѻýҕl>Minimal Link Between Eczema and Most Cancersѻýҕl> Study finds severe eczema tied to small risk for lymphoma Jun 30, 2020
<ѻýҕl>Cancer Immunotherapy Tied to Severe COVID-19 Outcomesѻýҕl> Nearly threefold increased risk of hospitalization, severe respiratory illness Jun 25, 2020
<ѻýҕl>Worse Blood Cancer Outcomes in Hispanicsѻýҕl> Diagnosis at earlier age, worse survival, especially for those on U.S.-Mexico border Jun 24, 2020
<ѻýҕl>Keytruda Tops Adcetris in Head-to-Head Hodgkin's Trialѻýҕl> Checkpoint inhibitor improved PFS in refractory and transplant-ineligible cases Jun 15, 2020
<ѻýҕl>CAR T-Cell Therapy Impresses in Indolent NHLѻýҕl> Overall response rate exceeding 90% with axi-cel in relapsed/refractory setting May 31, 2020
<ѻýҕl>Nivolumab-Based Tx Effective in Early, Unfavorable Hodgkin'sѻýҕl> Interim results showed high CR rates and almost 100% PFS, OS at 12 months May 01, 2020
<ѻýҕl>COVID-19 Mortality Spikes in Patients With Lung, Blood Cancersѻýҕl> Those with metastatic disease also at special risk for poor outcomes Apr 28, 2020
<ѻýҕl>DOAC Works in Cancer-Related VTE, No Tradeoff in Bleedsѻýҕl> Apixaban monotherapy matches dalteparin in non-inferiority trial Mar 29, 2020
<ѻýҕl>New CAR-T Makes Case for Aggressive Lymphomasѻýҕl> Largest trial to date shows 73% ORR, 53% CR, potential for outpatient treatment Feb 25, 2020
<ѻýҕl>Stem-Cell Transplant Trial Ends in a Drawѻýҕl> Similar PFS with haploidentical bone marrow, double unrelated umbilical cord blood Feb 24, 2020
<ѻýҕl>Preemptive Anti-IL-6 May Cut Severe CRS With CAR-T Txѻýҕl> Targeting patients with high tumor burden reduced severe CRS by 50% Feb 22, 2020
<ѻýҕl>Higher Risk of Shingles Seen in Patients With Certain Cancersѻýҕl> Vaccine development may help with prevention of herpes zoster in this population Dec 31, 2019
<ѻýҕl>'Off-the-Shelf' Therapy Active After CAR T-Cell Failureѻýҕl> Bispecific antibody mosunetuzumab targets CD3, CD20; needs no ex vivo T-cell processing Dec 07, 2019
<ѻýҕl>No Cancer Risk Found With TNF Inhibitors in Psoriatic Arthritisѻýҕl> Expected cancer cases similar to those in general populace, study shows Jun 13, 2019
<ѻýҕl>Rheumatologist's Primer on Checkpoint Inhibitorsѻýҕl> Specialist reviews the landscape of cancer drugs' autoimmune side effects Apr 09, 2019
<ѻýҕl>Durable Responses With Keytruda in Later-Line SCLCѻýҕl> Plus umbralisib in marginal zone lymphoma and a next-generation TRK-targeted agent Apr 04, 2019
<ѻýҕl>Do Keloids Convey a Higher Cancer Risk?ѻýҕl> Taiwanese researchers show association between raised scars and cancers Mar 03, 2019
<ѻýҕl>Higher Risk of Shingles Seen in Patients With Certain Cancersѻýҕl> Vaccine development may help with prevention of herpes zoster in this population Dec 14, 2018
<ѻýҕl>ASH Poster Rounds: Adding BTK Inhibitor Safe in First-Line MCLѻýҕl> Plus: Lenalidomide upfront in PTCL; skipping RT in primary mediastinal B-cell lymphoma Dec 07, 2018
<ѻýҕl>Add-On Drugs Could Boost Efficacy, Tolerability of CAR T-Cell Therapiesѻýҕl> Studies test addition of targeted agents, immunotherapy Dec 03, 2018